Intravascular Imaging
Incorporated (i3)

Anatomy is necessary. It has never been sufficient.

Coronary artery disease is the leading cause of death on the planet. Cardiologists fight it largely by opening blocked arteries and propping them open with stents. To do that well, they need to see inside. Intravascular ultrasound has been the workhorse for decades, and it is genuinely good at what it does, which is measure walls, lumens, and the fit of a stent.

Here is the inconvenient part. A great deal of what actually kills people - inflamed plaque, unhealed stent struts laced with fibrin, quiet arterial dissections, the slow vasculopathy that creeps into transplanted hearts - is biological. It is happening at the molecular and cellular level. And a grayscale picture of anatomy, however crisp, mostly shrugs at biology.

So the field has spent years asking an awkward question: what if you could see both at the same time, in the same place, in a living patient? Plenty of imaging modalities can see molecular signals in a lab. Threading that capability down a one-millimeter wire into a beating human coronary artery is a different sport entirely.

A 3-French catheter that refuses to pick a side

"3-French" means roughly one millimeter across. Into that span, i3's engineers packed both an ultrasound transducer and an optical fiber, so the device captures structure and molecular signal in a single pass. The system then renders them together: a longitudinal map of the vessel, a cross-section, and a near-infrared fluorescence overlay drawn as a ring of color where "hot," biologically active tissue glows.

There is a useful accelerant in the chemistry. Near-infrared fluorescence imaging can lean on indocyanine green, or ICG - a dye already approved by the FDA - which pools in the lipid-rich, macrophage-heavy zones of permeable plaque. In other words, some of the hard regulatory groundwork for the contrast agent already exists.

Where the numbers do the arguing

A pre-commercial device company lives and dies on validation, not revenue. i3's strongest evidence so far is that the catheter has performed in the settings closest to a real patient: ex-vivo human coronary arteries and in vivo preclinical studies. The technology also rests on published research showing that an integrated NIRF-ultrasound catheter can actually be built small enough to work.

Credibility also comes from company i3 keeps. The catheter was designed in collaboration with Massachusetts General Hospital. The founders carry MGH/Harvard and TU Munich appointments. And i3 has appeared in the portfolio of Broadview Ventures, a backer focused on cardiovascular innovation. None of this is FDA clearance - the company is candid that pivotal human studies and a submission still lie ahead - but it is the right kind of scaffolding for a device this early.

Back to that moment in the cath lab

The bet i3 is making is that intravascular imaging is mid-transition - from describing arteries to interpreting them. If that's right, hybrid molecular-structural imaging stops being a research curiosity and becomes part of the standard checklist before a stent gets locked into place. The company's plan to upgrade the existing IVUS installed base, rather than rip it out, is a quietly pragmatic way to ride that shift.

• What you can do with it: see plaque inflammation, dissections, and stent healing during the procedure, not after.
• Who it helps: interventional cardiologists making irreversible decisions in real time - and the patients on the table.
• Why now: an already-approved dye (ICG) and a worldwide base of IVUS consoles lower two of the usual barriers.

Return to that decisive moment. The stent is going in. In the world i3 is building, the cardiologist is no longer reading the artery like rock - guessing at what's underneath. The fire is on the screen. The inflammation has a color. The unhealed strut is visible before it becomes a problem.

The artery still looks like plumbing. The difference is that now, finally, you can tell whether it's on fire. That is the whole point of i3.